U.S. to Provide Experimental Ebola Antibody to High-Risk Americans Abroad as Kenya Quarantine Plan Stalls Amid Protests

The Department of Health and Human Services confirmed on June 4, 2026, that Americans with high-risk exposures to Ebola will have access to the experimental antibody treatment MBP-134. MBP-134 is an antibody treatment developed by Mapp Biopharmaceuticals with funding from the Biomedical Advanced Research and Development Authority, an agency within HHS.

BARDA owns the doses, and the company could not disclose how many exist.

An American doctor named Peter Stafford contracted Ebola in the outbreak zone last month and was flown to Germany for care. His wife, also a doctor, and their four children were taken to Germany for quarantine. Stafford remains in care but is reportedly recovering.

Another doctor from the same Christian missionary group had a high-risk exposure and is in quarantine in the Czech Republic; he remains healthy. There are currently no other known exposures among Americans. An expert panel advising the World Health Organization deemed MBP-134 one of the products to be prioritized for testing in the current outbreak, which is occurring in the northeastern part of the Democratic Republic of the Congo and neighboring Uganda.

An HHS spokesperson said BARDA is coordinating a shipment of monoclonal antibodies for potential use in high-risk Americans exposed to the virus. The therapy would be used under the Food and Drug Administration’s investigational use mechanisms.

U.S. Government has been building a 50-bed quarantine station in Kenya for Americans who have had exposure to Ebola. The facility will also have high-containment beds for initial treatment of anyone who becomes ill. Opening of the camp, which was supposed to occur on May 29, 2026, was halted by a Kenyan court.